How much does Ozempic cost with Medicare in Colorado in 2027?

Ozempic (semaglutide) is a GLP-1 receptor agonist, a once-weekly injection approved for type 2 diabetes. Part D plans cover it for that use; drugs used only for weight loss sit outside Part D. In 2024, 19,699 Colorado Part D members filled Ozempic and paid an average of $63.16 per 30-day fill. CDC PLACES estimates diabetes among 9.7% of Adams County adults and obesity among 33.2%.

Ozempic under Medicare: Colorado 2024 figures and the 2027 negotiated price

Ozempic	Amount
Colorado Part D members who filled Ozempic (2024)	19,699
Colorado gross cost per 30-day fill (2024)	$889.59
Colorado patient share per 30-day fill (2024)	$63.16
Medicare negotiated price, 30 days (from Jan 1, 2027)	$274
What changed: negotiated price in 2026	None
A full 2027 year, 2027 standard design	$1,347
2024 list price, 30 days, and discount	$959 (71% off)
People with Part D using Ozempic, Rybelsus or Wegovy (2024)	2,282,000

Diabetes coverage versus weight loss

If you have type 2 diabetes, your Medicare drug plan can pay for Ozempic as it would any listed medicine, though some plans ask for prior authorization first. If you want a GLP-1 for weight management, Ozempic is not the route.

That gap is what the Medicare GLP-1 Bridge addresses. From July 1, 2026 to December 31, 2027, eligible people with Medicare drug coverage can get Wegovy, the Zepbound KwikPen or Foundayo for a $50 copay for a month. Ozempic is not on that list, people with type 2 diabetes are not eligible for the Bridge, and the $50 does not count toward your Part D totals. Our post on the GLP-1 Bridge explains the BMI rules and how to start.

The 2027 negotiated price for semaglutide

CMS negotiated $274 for a 30-day supply of the semaglutide group (Ozempic, Rybelsus and Wegovy), 71% below the 2024 list price of $959. The group drew $15.2 billion in Part D gross costs in 2024. The exact price varies by strength. No generic semaglutide appears on the FDA first generic approval lists through October 2026.

How the cap changes the math

In 2027, at the $274 negotiated price with a $700 deductible, two full-price months and a $182.50 March fill clear the deductible, then fills run $68.50. The year comes to $1,347, under the $2,400 limit. Your plan's copay design will move these numbers.

What changed from 2026: with no negotiated price, a fill at Colorado's 2024 gross cost of $889.59 used up the $615 deductible in January and reached the $2,100 cap by August.

Help with a front-loaded year

Deductible months land early in 2027 too, so the Medicare Prescription Payment Plan can suit Ozempic users: a January fill at $274 becomes a first bill of about $22.83. Novo Nordisk's 2026 rules say Medicare beneficiaries with prescription drug coverage are no longer eligible to get Ozempic through its patient assistance program. Extra Help remains open to people under the 2026 limit of $23,940 income for one person.

Ozempic, Rybelsus and Wegovy: one price group

All three brands contain semaglutide. Ozempic is the weekly pen for type 2 diabetes, Rybelsus is a daily tablet for the same condition, and Wegovy is the higher-dose version used for weight management and heart risk. CMS negotiated them together, so the 2027 price covers whichever of the three your plan lists for a covered use.

Ozempic also carried the steepest gross bill of any drug on these pages: $889.59 per month-equivalent in Colorado during 2024, and $1,387.09 per national claim in early 2026, which is why the 2027 negotiated price matters more for semaglutide than for most drugs.

Questions for an Ozempic plan review

Bring the pen you use, because Ozempic pens deliver different weekly doses and plans can set quantity limits per pen. Ask whether prior authorization needs a diabetes diagnosis code or a recent A1C result from your doctor, whether pen needles are covered as Part D supplies, and what the plan does if your prescriber later moves you to Rybelsus tablets or to tirzepatide (Mounjaro), a different GLP-1 based medicine with its own spot on each plan list.

Related questions

Sources

1. CMS Selected Drug List and Negotiated Prices (Maximum Fair Price) data file, September 21, 2026 Centers for Medicare & Medicaid Services
2. CMS fact sheet: negotiated prices for initial price applicability year 2027 Centers for Medicare & Medicaid Services
3. CMS Announcement of Calendar Year 2027 Medicare Advantage Capitation Rates and Part C and Part D Payment Policies Centers for Medicare & Medicaid Services
4. CMS Medicare Part D Prescribers by Geography and Drug, 2024 (Colorado) Centers for Medicare & Medicaid Services
5. CMS Medicare Quarterly Part D Spending by Drug Centers for Medicare & Medicaid Services
6. CMS: How much does Medicare drug coverage cost? Centers for Medicare & Medicaid Services
7. CMS: Medicare GLP-1 Bridge Centers for Medicare & Medicaid Services
8. FDA: First Generic Drug Approvals (2026) U.S. Food and Drug Administration
9. NovoCare: Patient Assistance Program 2026 eligibility Novo Nordisk
10. CMS: Medicare Prescription Payment Plan, before using this payment option Centers for Medicare & Medicaid Services
11. CDC PLACES: Local Data for Better Health, County Data (2025 release) Centers for Disease Control and Prevention

Please note: We do not offer every plan available in your area. Currently we represent 10 organizations which offer 106 products in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options.Headwaters Health and Wealth is not connected with or endorsed by the United States government or the federal Medicare program. Medicare has neither endorsed nor reviewed this information.